Welcome to our dedicated page for Oculis Holding SEC filings (Ticker: OCSAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Oculis Holding's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Oculis Holding's regulatory disclosures and financial reporting.
Oculis Holding AG is calling shareholders to its 2026 Annual General Meeting on May 13, 2026 in Zug, Switzerland, with an in-person meeting and broadcast.
The agenda covers approval of the 2025 annual and consolidated financial statements, carrying forward a balance sheet loss of CHF 80,247,000, and granting discharge to the board and executive committee. Shareholders will vote on re-electing eight directors, electing a new director, appointing compensation committee members, re-electing PricewaterhouseCoopers as auditor, and electing Blum & Partner AG as independent proxy.
Compensation proposals include up to USD 572,000 fixed and USD 2,150,000 equity-based pay for the board, and up to USD 2,500,000 fixed, USD 1,800,000 variable, and USD 18,000,000 equity-based compensation for the executive committee. The board also seeks to increase the capital band so it can issue up to 31,020,888 additional shares and to expand conditional share capital for employee plans to 12,677,700 shares.
A business update highlights three late-stage programs: OCS-01 eye drops for diabetic macular edema with Phase 3 DIAMOND trial readouts expected in June 2026 and a planned U.S. NDA submission in Q4 2026; Licaminlimab for dry eye disease in the PREDICT-1 registrational trial with topline data expected around late 2026; and Privosegtor, which has Breakthrough Therapy, Orphan Drug and PRIME designations and is entering the PIONEER registrational program for optic neuritis and NAION. Oculis reports oversubscribed equity financings exceeding $200 million in 2025 and is targeting disease areas that together represent estimated market opportunities of over $30 billion.
Oculis Holding AG is calling shareholders to its 2026 Annual General Meeting on May 13, 2026 in Zug, Switzerland, with an in-person meeting and broadcast.
The agenda covers approval of the 2025 annual and consolidated financial statements, carrying forward a balance sheet loss of CHF 80,247,000, and granting discharge to the board and executive committee. Shareholders will vote on re-electing eight directors, electing a new director, appointing compensation committee members, re-electing PricewaterhouseCoopers as auditor, and electing Blum & Partner AG as independent proxy.
Compensation proposals include up to USD 572,000 fixed and USD 2,150,000 equity-based pay for the board, and up to USD 2,500,000 fixed, USD 1,800,000 variable, and USD 18,000,000 equity-based compensation for the executive committee. The board also seeks to increase the capital band so it can issue up to 31,020,888 additional shares and to expand conditional share capital for employee plans to 12,677,700 shares.
A business update highlights three late-stage programs: OCS-01 eye drops for diabetic macular edema with Phase 3 DIAMOND trial readouts expected in June 2026 and a planned U.S. NDA submission in Q4 2026; Licaminlimab for dry eye disease in the PREDICT-1 registrational trial with topline data expected around late 2026; and Privosegtor, which has Breakthrough Therapy, Orphan Drug and PRIME designations and is entering the PIONEER registrational program for optic neuritis and NAION. Oculis reports oversubscribed equity financings exceeding $200 million in 2025 and is targeting disease areas that together represent estimated market opportunities of over $30 billion.
Oculis Holding AG reported a 2025 net loss of CHF 98.96m, compared with a CHF 85.78m loss in 2024, as it advanced late-stage ophthalmic drug development. Research and development expenses rose to CHF 57.1m, while general and administrative costs reached CHF 25.8m, driven mainly by clinical programs and share-based compensation.
Despite ongoing losses, Oculis strengthened its balance sheet. Cash and cash equivalents were CHF 81.33m and short-term financial assets were CHF 131.68m as of December 31, 2025, following underwritten offerings totaling CHF 178.9m in gross proceeds. Total equity increased to CHF 196.07m and total assets to CHF 235.96m, giving the company resources to fund its pipeline.
Separately, Oculis renewed its at-the-market equity program by entering into an amended and restated sales agreement with Leerink Partners tied to a new Form F-3 shelf registration. The ATM program permits offers and sales, at the company’s discretion, of ordinary shares up to an aggregate offering price of $100m through Leerink Partners as sales agent.
Oculis Holding AG reported a 2025 net loss of CHF 98.96m, compared with a CHF 85.78m loss in 2024, as it advanced late-stage ophthalmic drug development. Research and development expenses rose to CHF 57.1m, while general and administrative costs reached CHF 25.8m, driven mainly by clinical programs and share-based compensation.
Despite ongoing losses, Oculis strengthened its balance sheet. Cash and cash equivalents were CHF 81.33m and short-term financial assets were CHF 131.68m as of December 31, 2025, following underwritten offerings totaling CHF 178.9m in gross proceeds. Total equity increased to CHF 196.07m and total assets to CHF 235.96m, giving the company resources to fund its pipeline.
Separately, Oculis renewed its at-the-market equity program by entering into an amended and restated sales agreement with Leerink Partners tied to a new Form F-3 shelf registration. The ATM program permits offers and sales, at the company’s discretion, of ordinary shares up to an aggregate offering price of $100m through Leerink Partners as sales agent.
Oculis Holding, a late clinical-stage biopharmaceutical company focused on ophthalmic and neuro‑ophthalmic diseases, reports continued pre‑revenue investment in its pipeline, including OCS‑01 for diabetic macular edema, Licaminlimab for dry eye disease and Privosegtor for optic neuritis and related conditions.
For the year ended December 31, 2025, Oculis recorded a net loss of CHF 99.0 million, compared with CHF 85.8 million in 2024, bringing accumulated losses to CHF 384.5 million. The company held CHF 213.0 million in cash, cash equivalents and short‑term financial assets, which it believes will fund operations for at least the next twelve months. As of December 31, 2025, it had 57,984,438 ordinary shares, 2,104,906 warrants to purchase ordinary shares and 60 employees.
Oculis Holding, a late clinical-stage biopharmaceutical company focused on ophthalmic and neuro‑ophthalmic diseases, reports continued pre‑revenue investment in its pipeline, including OCS‑01 for diabetic macular edema, Licaminlimab for dry eye disease and Privosegtor for optic neuritis and related conditions.
For the year ended December 31, 2025, Oculis recorded a net loss of CHF 99.0 million, compared with CHF 85.8 million in 2024, bringing accumulated losses to CHF 384.5 million. The company held CHF 213.0 million in cash, cash equivalents and short‑term financial assets, which it believes will fund operations for at least the next twelve months. As of December 31, 2025, it had 57,984,438 ordinary shares, 2,104,906 warrants to purchase ordinary shares and 60 employees.
Oculis Holding reported a 2025 net loss of CHF 99.0 million (vs. CHF 85.8 million in 2024) as it stepped up investment in its late‑stage pipeline. Cash, cash equivalents and short‑term investments rose to CHF 213.0 million, or $268.7 million, helped by $210.0 million of equity financings in February and November 2025, giving a cash runway into 2029.
During 2025, the company obtained FDA Breakthrough Therapy designation for Privosegtor in optic neuritis and initiated the PIONEER‑1 registrational trial. Both Phase 3 DIAMOND trials of OCS‑01 in diabetic macular edema enrolled over 800 patients, with topline data expected in Q2 2026 and a possible NDA in Q4 2026 if results are positive. Oculis also launched the genotype‑based PREDICT‑1 registrational trial of Licaminlimab in dry eye disease, with topline results targeted for Q4 2026.
Oculis Holding reported a 2025 net loss of CHF 99.0 million (vs. CHF 85.8 million in 2024) as it stepped up investment in its late‑stage pipeline. Cash, cash equivalents and short‑term investments rose to CHF 213.0 million, or $268.7 million, helped by $210.0 million of equity financings in February and November 2025, giving a cash runway into 2029.
During 2025, the company obtained FDA Breakthrough Therapy designation for Privosegtor in optic neuritis and initiated the PIONEER‑1 registrational trial. Both Phase 3 DIAMOND trials of OCS‑01 in diabetic macular edema enrolled over 800 patients, with topline data expected in Q2 2026 and a possible NDA in Q4 2026 if results are positive. Oculis also launched the genotype‑based PREDICT‑1 registrational trial of Licaminlimab in dry eye disease, with topline results targeted for Q4 2026.
Oculis Holding AG filing reports a proposed sale of 25,000 common shares through UBS Financial Services on 09/23/2025, with an aggregate market value of $442,500 based on the notice. The filing shows 43,662,402 shares outstanding. The shares were acquired on 03/02/2023 as issuance of earnout shares from the issuer and fully paid on that date. The filer reports no sales of the issuer's securities in the past three months and includes the standard representation that the seller is unaware of any undisclosed material adverse information.